Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp.
SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp., as detailed below:
Bellerophon Therapeutics, Inc.
Johnson & Weaver, LLP, is investigating potential violations of federal and state laws by certain officers and directors of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH).
On February 13, 2015, Bellerophon's sold 13 million shares of stock in its initial public stock offering (the "IPO"), raising $60.0 million in new capital. However, since the IPO, Bellerophon's stock has imploded, on October 25, 2016, the stock closed at $1.40.
Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business operations and financial prospects were not as strong as represented in the Registration Statement
If you are a Bellerophon shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.
KemPharm, Inc.
Johnson & Weaver, LLP is investigating potential violations of federal and state laws by certain officers and directors of KemPharm, Inc. (NASDAQ: KMPH).
On April 16, 2015, KemPharm's stock traded as high as $12.33, the same day the Company sold 5.09 million shares of stock in its initial public stock offering (the "IPO"), raising nearly $60 million in new capital. However, since the IPO, KemPharm's stock has imploded, falling from its high of $23.63 in September 2015 to close at $3.50 on October 25, 2016.
Recently, on May 5, 2016, KemPharm announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted on Apadaz, decisively by a vote of 16 to 4 that Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted 18 to 2 against inclusion of abuse-deterrent labeling for the product. On this news, the stock dropped 56%. Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business metrics and financial prospects were not as strong as represented in the Registration Statement.
If you are a KemPharm shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.
Neos Therapeutics, Inc.
Johnson & Weaver, LLP is investigating potential violations of federal laws by certain officers and directors of Neos Therapeutics, Inc. (NASDAQ:NEOS).
On July 23, 2015, Neos sold 4.8 million shares of stock in its initial public stock offering (the "IPO"), raising $72.0 million in new capital. However, since the IPO, Neos' stock has imploded, falling from a high of $27.09 in August 2015 to close at $6.27 on October 25, 2016.
Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business metrics, operations and financial prospects were not as strong as represented in the Registration Statement.
If you are a Neos shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.
CommVault Systems, Inc.
Johnson & Weaver, LLP, is investigating potential violations of federal and state laws by certain officers and directors of CommVault Systems, Inc. (NASDAQ:CVLT).
On September 30, 2016, a federal court denied a motion to dismiss a securities fraud class action filed against CommVault and certain executives. CommVault provides data and information management software applications and related services in North America, Europe, Australia and Asia.
The Complaint alleges that during the Class Period, CommVault and certain of its senior executives violated provisions of the Exchange Act by issuing false and misleading press releases, financial statements, filings with the Securities and Exchange Commission ("SEC"), and statements during investor conference calls. CommVault derives about half of its annual revenue from licensing its software applications, with the remaining half of the Company's revenue coming in the form of services and maintenance revenue. The complaint alleges CommVault misrepresented revenue growth by booking and subsequently recognizing deferred software licensing revenue to mask slowing revenue growth, while at the same time denying that revenue growth was in fact decelerating. The Company also misrepresented that it was increasing investments in its sales force and hiring more sales employees in order to continue to drive growth through the fiscal year 2014 and beyond. As a result of these misrepresentations, CommVault stock traded at artificially inflated prices during the Class Period.
If you have held CommVault shares continuously since at least May 6, 2013, you may have standing to hold CommVault harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
If you are a CommVault shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.
Resource Capital Corp.
Johnson & Weaver, LLP, is investigating potential violations of federal and state laws by certain officers and directors of Resource Capital Corp. (NYSE:RSO).
On October 5, 2016, a federal court denied a motion to dismiss a securities fraud class action filed against Resource Capital and certain executives. Resource Capital is a diversified real estate investment trust, primarily focuses on originating, holding and managing commercial mortgage loans and other commercial real estate-related debt and equity investments in the United States.
The complaint alleges, throughout the Class Period, October 31, 2012 and August 5, 2015, Resource Capital and certain of its senior executives deceived public investors by failing to alert them of a particularly risky and dangerous loan within their portfolio. The loan in question was a mezzanine loan secured by a number of luxury hotels (the "Mezzanine Loan"). When initially acquired in 2007, the Mezzanine Loan was secured by 13 hotels owned by The Blackstone Group ("Blackstone"). Three of the hotels serving as collateral were located in Puerto Rico and as time progressed, these three hotels came to be the only three assets securing the Mezzanine Loan. Defendants never disclosed this to investors. Since 2006, however, Puerto Rico's economy has been suffering from a crippling recession.
If you have held Resource Capital shares continuously since at least October 31, 2012, you may have standing to hold Resource Capital harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
If you are a Resource Capital shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]
Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO
SOURCE Johnson & Weaver, LLP
Share this article